Key Takeaways
- Researchers studied cannabinoids CBG and CBC on lung cancer cells, revealing both induce apoptosis and damage mitochondria.
- CBG showed stronger effects than CBC in killing cancer cells and disrupting their energy production.
- Blocking the PPARĪ± receptor significantly reduced CBG’s pro-apoptotic effects, marking a key discovery for cannabinoid research.
- CBG and CBC have shown anticancer potential, but further studies are needed to confirm their effectiveness in humans.
- The study emphasizes the importance of ongoing research into cannabinoids and their therapeutic roles in cancer care.
Scientists at the Institute of Pharmacology and Toxicology at Rostock University Medical Center and the University of Rostock set out to study two cannabinoids that get far less attention than THC or CBD. According to the study published in Antioxidants, the researchers tested CBG and CBC on A549 and H460 cells, two widely used human lung cancer cell lines.
The results showed that both cannabinoids caused concentration-dependent cell death in both cell lines. The cells showed clear signs of apoptosis, which is the scientific term for programmed cell death. Researchers observed activation of caspase-8, caspase-9 and caspase-3/7 (enzymes that drive the apoptosis process), a loss of mitochondrial membrane potential, and a buildup of cytochrome c outside the mitochondria. All of these are recognized markers that a cell is shutting itself down.
CBG also raised levels of ATF4, a transcription factor tied to stress responses, autophagy and apoptotic signaling, and increased PARP cleavage, another apoptosis marker. Both cannabinoids pushed up mitochondrial superoxide levels and lowered the cells’ oxygen consumption rate, signaling that the cells’ energy-producing machinery was struggling. CBG specifically reduced NDUFB8, a piece of the respiratory chain complex that cells depend on for energy production.
How Do CBG and CBC Actually Kill Lung Cancer Cells in the Lab, According to the Research?
The short version: by damaging the cell’s power plants. Mitochondria are responsible for generating the energy a cell needs to survive and function. When CBG and CBC were introduced to the lung cancer cells, researchers saw structural damage to the mitochondria, confirmed through electron microscopy images showing altered mitochondrial cristae and, in some cases, swollen mitochondria.
This mitochondrial stress set off a chain reaction. As membrane potential dropped and cytochrome c leaked into the cytosol, the cells activated their internal apoptosis machinery. The study also found increased formation of LC3-II, a marker for autophagy, suggesting the cells were also trying (and largely failing) to clean up damaged components through a separate cellular process.
What stood out to the researchers is that CBG produced stronger effects than CBC across nearly every measurement, including cell viability reduction and mitochondrial respiration inhibition. That difference set the stage for the next part of the study: figuring out which receptor was responsible for CBG’s more pronounced activity.
Why Does PPARĪ± Matter for CBG’s Effects?
This is where the study gets genuinely interesting for cannabinoid researchers. The team tested a handful of receptor blockers, including ones that target CB1, CB2, TRPV1, TRPM8 and PPARĪ³, hoping to figure out which pathway CBG and CBC were using to kill cancer cells. None of those blockers reversed the effect.
Then they tried blocking PPARĪ±, a transcription factor that regulates genes tied to fat metabolism and has been linked in other research to cancer cell toxicity. When PPARĪ± was blocked with the compound GW6471, CBG’s cell-killing and pro-apoptotic effects were significantly reduced, in some cases almost completely reversed in the A549 cell line. A second, more selective PPARĪ± blocker called NXT629 produced the same pattern, reinforcing that this receptor is doing real work here.
CBC’s effects, by comparison, were only mildly affected by PPARĪ± blockers, suggesting it may rely on a different (and still unidentified) mechanism. The researchers describe this as the first study to connect CBG’s cancer cell death activity directly to PPARĪ±, which gives future researchers a specific target to study further.
Beard Bros Pharms has touched on cannabinoid receptor science before. If you want more background on how CB1 and CB2 receptors work and how apoptosis fits into cannabinoid cancer research generally, we covered that ground in an earlier piece revisiting decades-old NIH tumor research.
What Has Been Published about Cannabinoid Cancer Research Lately?
This study came out in June, and cannabinoid cancer research has not slowed down since. A few notable additions worth knowing about:
In July, researchers found that CBD, CBG and CBN reduced viability in two human bile duct cancer cell lines, disrupted mitochondrial function and lowered markers of cell proliferation. In August, a separate team paired CBN and CBG with melatonin and found the combination enhanced the chemotherapy drug temozolomide against glioblastoma cells across three genetically distinct cell lines. September brought a study pairing CBD and CBG with sodium pentaborate against colorectal cancer cells, with some combinations showing synergy.
October added a study from Hunter College and the CUNY Graduate Center testing chemically modified CBC-derived compounds against a panel of 60 human cancer cell lines, with one synthetic derivative showing notable activity against prostate cancer cells. By mid-October, The Marijuana Herald had tracked at least 30 separate CBG studies published that year alone, a sign that interest in this minor cannabinoid keeps growing. For more on CBG’s role in brain tumor research specifically, we’ve written about that separately.
Is This Really New Ground for Cannabinoid Cancer Research?
CBG and CBC are not newcomers to cancer research, but they have historically received far less attention than THC and CBD. Researchers first noted anticancer effects from both compounds back in 2006, and since then CBG has shown pro-apoptotic effects in cholangiocarcinoma, colorectal carcinoma, glioblastoma, mesothelioma and prostate cancer cells. CBC has shown similar activity in bladder, colon and pancreatic cancer cells.
What makes the Rostock study stand out is the PPARĪ± connection. Prior cannabinoid research linking PPARĪ± to cell death has mostly focused on THC, CBD and their combination in melanoma cells. Tying CBG specifically to this pathway in lung cancer cells is a new data point, and it gives researchers a clearer direction for follow-up work.
For readers wanting broader context on where cannabinoid oncology research currently stands, our earlier review of the scientific literature on cannabinoids in oncology is a good place to start. We’ve also covered related findings on ovarian cancer cells responding to combined CBD and THC exposure, which shows a similar pattern of cannabinoids working through programmed cell death pathways across different cancer types.
What Does This Actually Mean for Patients and Cannabis Users?
Here’s the part that matters most: this is a laboratory cell study. The researchers treated isolated lung cancer cells in petri dishes with CBG and CBC under controlled conditions. That is meaningfully different from a clinical trial involving actual patients, and it is a long way from evidence that smoking, vaping or ingesting CBG or CBC would shrink a tumor in a human body.
The study authors themselves describe CBG and CBC as compounds that “warrant further investigation,” not compounds with proven anticancer benefits in people. No dosing information from this study translates to human use, and nothing here should be read as medical advice or a replacement for conversations with an oncology team.
That said, there is a growing and legitimate body of research showing cannabis can play a supportive role in cancer care, particularly around symptom management. A University of Kentucky survey of 237 radiation therapy patients found that 80% of recent cannabis users reported improved symptoms and 89% reported better quality of life, which we covered in detail here. A separate Minnesota study of over 6,600 cancer patients found similar symptom relief patterns with a low rate of mostly mild side effects, also covered on our site.
Anyone navigating a cancer diagnosis and considering cannabis should talk with their care team first, especially if chemotherapy, radiation or other treatments are already part of the plan.
What’s Next for CBG and CBC Research?
The Rostock team was upfront about the gaps in their work. They could not pin down a specific receptor driving CBC’s effects, and their PPARĪ± findings for CBG relied on pharmacological blockers rather than genetic knockdown studies, which would offer stronger confirmation. They called for more research using tools like siRNA to directly silence PPARĪ± and for testing these mechanisms in other tumor types beyond lung cancer.
Given how many CBG and CBC studies have already come out since June, it seems safe to expect more detail on these mechanisms before the end of the year. For now, this study adds a solid piece to a growing puzzle: two often-overlooked cannabinoids, one newly identified receptor pathway, and a lot of open questions still worth chasing down.
Want to stay current on cannabinoid research? Our news section tracks new studies like this one as soon as researchers publish them.
Frequently Asked Questions
In laboratory testing on two human lung cancer cell lines (A549 and H460), CBG triggered concentration-dependent cell death and apoptosis. Researchers observed this effect in isolated cells, not in human patients, so it doesn’t prove that CBG treats lung cancer.
CBC also caused cell death and apoptosis in the same lung cancer cell lines, but its effects were generally weaker than CBG’s and did not rely as heavily on the PPARĪ± receptor pathway identified in the study.
PPARĪ± is a transcription factor that regulates genes involved in fat metabolism. Researchers found that blocking PPARĪ± reduced CBG’s cancer cell-killing effects, suggesting CBG activates this receptor as part of how it triggers apoptosis in lung cancer cells.
No. CBG, like CBC, is classified as a non-psychoactive phytocannabinoid.It doesn’t cause the intoxicating effects that THC does, which is one reason researchers are increasingly eager to study its other biological activities.
No. This research is preclinical and conducted on isolated cells, not people. Cannabinoids are not a proven cancer treatment or cure, and anyone with a cancer diagnosis should speak with their oncology team before using cannabis products alongside or instead of prescribed treatment.
